Dose-response efficacy of valsartan, a new angiotensin II receptor blocker

Journal of Human Hypertension

Volumn 13, Issue 4, 1999, Pages 275-281

  Pool, James L ^a,c   Glazer, R ^b   Chiang, Y T ^b   Gatlin, M ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Angiotensin II receptor antagonist; Hypertension; Valsartan

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; RENIN; VALSARTAN;

ADULT; AGED; ANGIOTENSIN BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEMALE; HEADACHE; HUMAN; HYPERTENSION; LIBIDO; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PLASMA RENIN ACTIVITY; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; VERTIGO;

EID: 0032945662     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000788     Document Type: Article

References (17)

1. Sassano, P et al. Antihypertensive effect of enalapril as first-step treatment of mild and moderate uncomplicated essential hypertension: evaluation by two methods of blood pressure measurement. Am J Med 1984; 20 August: 18-22.
2. Frishman WH, Goldberger J, Sherman D. Enalapril, hydrocholorothiazide, and combination therapy in patients with moderate hypertension. J Clin Hypertens 1987; 3: 520-527.
3. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann Int Med 1992; 117: 234-242.
4. Kaufman MP, Coleridge HM, Coleridge JCG, Baker DG. Bradykinin stimulates afferent vagal C-fibers in intrapulmonary airways of dogs. Am Physiol Soc 1980; 48: 511-517.
5. Foote EF, Halstenson CE. New therapeutic agents in the management of hypertension: angiotensin II receptor antagonists and renin inhibitors. Ann Pharmacother 1993; 27: 1495-1503.
6. Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346: 1403-1407.
7. Black HR et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor lisinopril. J Hum Hypertens 1997; 11: 483-489.
8. Mallion J-M et al. Valsartan, a new angiotensin II antagonist: Efficacy and tolerability compared with an angiotensin converting enzyme inhibitor enalapril in essential hypertension. Blood Pressure Monitoring 1997; 2: 179-185.
9. Criscione L et al Valsartan: preclinical and clinical profile of an antihypertensive angiotensin II antagonist. Cardiovasc Drug Rev 1996; 13: 230-250.
10. Herblin WF et al Angiotensin II receptor heterogeneity. Am J Hypertens 1991; 4: 299S-302S.
11. Yamada T, Horiuchi M, Dzau VJ. Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci 1996; 93: 156-160.
12. Ohkubo N et al. Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 1997; 96: 3954-3962.
13. Müller P et al Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol 1994; 47: 231-245.
14. Müller P et al Single and multiple dose phase I trials with the angiotensin II antagonist valsartan. J Hypertens 1993; 11 (Suppl 5): S459.
15. Lipicky RJ. Trough:peak ratio: the rationale behind the United States Food and Drug Administration recommendations. J Hypertens 1994; 12 (Suppl): S17-S19.
16. Sever PS. Clinical profile of the novel angiotensin II type blocker candesartan cilexitil. J Hypertens Suppl 1997; 15(6): S9-S12.
17. Man in't Veld AJ. Clinical overview of irbesartan: expanding the therapeutic window in hypertension. J Hypertens Suppl 1997; 15(7): S27-S33.